Literature DB >> 8560659

Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer.

Y Hasui1, K Marutsuka, Y Asada, Y Osada.   

Abstract

OBJECTIVES: A number of studies have demonstrated that urokinase-type plasminogen activator (u-PA) is one of the major enzymes in the development of cancer invasion and metastasis. We examined the possibility that u-PA content is an independent prognostic marker for superficial bladder cancer.
METHODS: The u-PA content was estimated in superficial bladder cancer from 52 patients undergoing transurethral resection for the first time. The survival rates of the patients were calculated and the prognostic values for u-PA content (less than 8 ng/mg protein versus more than 8 ng/mg), Stage (pTa or pT1), grade (1 and 2 versus 3), number (single versus multiple), and size (less than 1 cm versus more than 1 cm) of tumor were determined by a multivariate regression model.
RESULTS: Development of cancer invasion and metastasis was observed in 3 and 8 patients, respectively. The survival rate of the patients with high u-PA content was significantly lower than those with low u-PA content (P < 0.005). In the multivariate regression analysis, u-PA content was the most important risk factor for the prognosis, compared with the other factors: tumor stage, grade, multiplicity, and size.
CONCLUSIONS: We have first shown that u-PA content is a new independent prognostic marker in patients with superficial bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8560659     DOI: 10.1016/s0090-4295(99)80378-1

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  1 in total

Review 1.  Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets.

Authors:  Nico C Grossmann; Victor M Schuettfort; Benjamin Pradere; Marco Moschini; Fahad Quhal; Hadi Mostafaei; Francesco Soria; Satoshi Katayama; Ekaterina Laukhtina; Keiichiro Mori; Reza Sari Motlagh; Cédric Poyet; Mohammad Abufaraj; Pierre I Karakiewicz; Shahrokh F Shariat; David D'Andrea
Journal:  Onco Targets Ther       Date:  2021-01-13       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.